Latest Share Chat

Hikma Pharma shares rise on 'unsolicited enquiries'

Fri, 01st Mar 2013 11:42

Hikma Pharmaceuticals on Friday confirmed that it has received several unsolicited enquiries in its Injectables business and is now undertaking a review of strategic options for its future. In a statment the group's Chief Executive Officer said: "We have received a number of unsolicited expressions of interest in our Injectables business and will consider the best option for shareholders."The share price rose 4.85% to 908p by 12:05.NR

Related Shares

More News

3 May 2024 09:14

LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

26 Apr 2024 13:36

UK dividends calendar - next 7 days

25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth readi...

25 Apr 2024 10:15

Hikma Pharmaceuticals backs outlook after making strong start to 2024

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reported an encouraging start to the year supported by all three business segments.

25 Apr 2024 08:01

Hikma delivers strong Q1, holds on to guidance

(Sharecast News) - Pharmaceuticals group Hikma said it has made a "strong and encouraging start" to 2024, with all three business segments performing ...